Quantcast

Latest Access Pharmaceuticals Inc. Stories

2014-07-22 08:32:06

New product offers treatment to significant unmet medical need in supportive cancer care DALLAS and NEW YORK, July 22, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard(TM), its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of...

2014-07-08 12:28:56

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets DALLAS and NEW YORK, July 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Hong Kong Patent Office that a patent for MuGard(TM) has been granted. The patent (HK1126134) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Being awarded...

2014-05-01 08:31:31

NEW YORK, May 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the data from its multi-institutional post-approval trial of MuGard(®) that was recently published in Cancer, has been selected as a cover article in the premier publication. Cancer, the journal of the American Cancer Society is one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess...

2014-04-15 08:30:20

NEW YORK, April 15, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that positive results from a study conducted at Nova Southeastern University were presented recently at the Frontiers in Oral Medicine 2014 conference, hosted by the American Academy of Oral Medicine, in Orlando, Florida. The poster, entitled "Effectiveness of a Polymer-Based Muco-Adhesive (MuGard(®)) in the Healing of Oral Ulcers in Erosive Lichen...

2014-04-08 08:32:03

Additional Mucoadhesive Polymer Hydrogel Technology Formulation; Seeking Marketing Partners NEW YORK, April 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard(TM), for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved and used in the US, Japan and other countries,...

2014-04-01 08:29:19

Expanding Product Offerings; Building IP Portfolio; Seeking Global Marketing Partners NEW YORK, April 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and...

2014-03-26 08:29:22

Company Seeking Global Marketing Partners for its Proprietary Vitamin B-12 Drug Delivery Technology NEW YORK, March 26, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and...

2014-03-21 08:25:00

Leveraging Proprietary Mucoadhesive Polymer Hydrogel Technology to Expand Product Offerings; Seeking Global Marketing Partners NEW YORK, March 21, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has advanced development of a new proprietary product, called ProctiGard(TM), for the treatment of radiation proctitis. Radiation proctitis ("RP") is a significant unmet medical need, with no well-established standard of care. It is estimated that there are...

2014-03-11 08:31:40

NEW YORK, March 11, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) today announced that it had entered into an exclusive license agreement with HANMI PHARMACEUTICAL CO., LTD. (KSE: 128940) related to MuGard commercialization in South Korea. Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard is an oral mucoadhesive that is designed to manage oral...

2014-02-18 08:31:32

Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased Severity of Oral Mucositis by WHO Score NEW YORK, Feb. 18, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced the online early publication of the final results of its post-approval marketing study of MuGard(®) in Cancer, the journal of the American Cancer Society and one of the oldest peer-reviewed journals...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related